NASDAQ:PLYX

Polaryx Therapeutics Q3 2026 Earnings Results & Report

Polaryx Therapeutics logo
$1.55 -0.06 (-3.73%)
As of 02:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Polaryx Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.07 versus the -$0.05 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
7:00 AM ET

Polaryx Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Polaryx Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Polaryx Therapeutics Q3 2026 Earnings FAQ

Polaryx Therapeutics (NASDAQ:PLYX) reported earnings of -$0.07 per share for Q3 2026, missing the consensus estimate of -$0.05. The report was announced on Thursday, November 12, 2026.

Polaryx Therapeutics Earnings Headlines

HC Wainwright Issues Optimistic Forecast for PLYX Earnings
CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Polaryx Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Polaryx Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Polaryx Therapeutics and other key companies, straight to your email.

About Polaryx Therapeutics

Polaryx Therapeutics (NASDAQ:PLYX) is a biotechnology company focused on developing treatments for rare genetic diseases. Its research and development activities target conditions with significant unmet medical needs, including disorders that affect the nervous system and metabolism.

The company’s work centers on advancing drug candidates for these conditions. Publicly available information about its specific products, commercial operations, geographic reach and leadership is limited.

View Polaryx Therapeutics Profile